ImmunityBio IBRX Insider Ownership

Updated Oct 10, 2026

In the last 12 months, insiders at ImmunityBio made open-market sales of $9.51 million (1.04Mn shares) and bought no shares on the open market.

• By number of insiders, ImmunityBio saw 3 insiders sell on the open market over the past 12 months and none buy.
• Barry J. Simon (Director) sold the most ImmunityBio stock on the open market over the past 12 months, $4.41 million (475K shares), most recently on October 5, 2026.
• In transactions other than open-market trades, ImmunityBio insiders acquired 5.83Mn shares through option exercises and conversions and gave up 500.56K shares to cover taxes or exercise prices over the past 12 months.
• Business Quant data puts insider holdings in IBRX at 658.74Mn shares across insiders' latest Form 4 filings, down 0.02% from 658.87Mn shares at the end of Q2 2026 and up 0.69% from 654.21Mn shares at the end of Q3 2025.
• Direct holdings account for 33.81Mn shares (5.13%) of IBRX's insider total, and indirect holdings through trusts, partnerships and family members for 624.93Mn shares (94.87%).
• Holdings in ImmunityBio stock are reported by 8 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• IBRX's three largest insider shareholders, per their latest Form 4 filings, are Patrick Soon-Shiong (Director, officer and 10% owner, 654.61Mn shares), Barry J. Simon (Director, 2.78Mn shares) and Richard Adcock (CEO & President, 562.27K shares).
• Of the shares held by IBRX insiders, 99.37% belong to Patrick Soon-Shiong.
• Institutional holders reported 19.27% of ImmunityBio's outstanding shares for Q2 2026; insiders' latest Form 4 filings put their stake at about 62.73%, and other investors, including the public, hold the remaining 18.00%.
• In the past year, 11 insiders of ImmunityBio submitted 30 Form 4 filings reporting trades, awards or other transactions.
• The insider holdings and trades above for ImmunityBio reflect Form 4 filings through October 6, 2026.